Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation

Neil M Bressler, Allison R. Edwards, Roy W. Beck, Christina J. Flaxel, Adam R. Glassman, Michael S. Ip, Craig Kollman, Baruch D. Kuppermann, Thomas W. Stone

Research output: Contribution to journalArticle

Abstract

Objective: To compare the effect of intravitreal triamcinolone acetonide with focal/grid photocoagulation on the progression of diabetic retinopathy. Methods: We performed an exploratory analysis of participants with diabetic macular edema randomly assigned to receive laser therapy or intravitreal triamcinolone acetonide (1 or 4 mg). Fundus photographs were obtained at baseline and 1, 2, and 3 years. The main outcome measure was progression to proliferative diabetic retinopathy or worsening of 2 or more severity levels on reading-center masked assessment of 7-field fundus photographs, plus additional eyes that received panretinal photocoagulation or had a vitreous hemorrhage. Results: From July 15, 2004, through May 5, 2006, 840 eyes from 693 participants were enrolled in the study and randomly assigned to receive laser therapy (n=330), 1 mg of triamcinolone acetonide (n=256), or 4 mg of triamcinolone acetonide (n=254). The cumulative probability of progression of retinopathy at 2 years was 31% (laser group), 29% (1-mg group), and 21% (4-mg group) (P=.64 in the 1-mg group and .005 in the 4-mg group compared with the laser group). These differences appeared to be sustained at 3 years. Conclusions: Intravitreal triamcinolone acetonide (4 mg) appeared to reduce the risk of progression of diabetic retinopathy. Given the exploratory nature of this analysis and because intravitreal triamcinolone adverse effects include cataract formation and glaucoma, use of this treatment merely to reduce the rates of progression of proliferative diabetic retinopathy or worsening of the level of diabetic retinopathy does not seem warranted at this time.

Original languageEnglish (US)
Pages (from-to)1566-1571
Number of pages6
JournalArchives of Ophthalmology
Volume127
Issue number12
DOIs
StatePublished - Dec 2009

Fingerprint

Triamcinolone Acetonide
Light Coagulation
Diabetic Retinopathy
Randomized Controlled Trials
Laser Therapy
Lasers
Vitreous Hemorrhage
Triamcinolone
Macular Edema
Glaucoma
Cataract
Reading
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. / Bressler, Neil M; Edwards, Allison R.; Beck, Roy W.; Flaxel, Christina J.; Glassman, Adam R.; Ip, Michael S.; Kollman, Craig; Kuppermann, Baruch D.; Stone, Thomas W.

In: Archives of Ophthalmology, Vol. 127, No. 12, 12.2009, p. 1566-1571.

Research output: Contribution to journalArticle

Bressler, Neil M ; Edwards, Allison R. ; Beck, Roy W. ; Flaxel, Christina J. ; Glassman, Adam R. ; Ip, Michael S. ; Kollman, Craig ; Kuppermann, Baruch D. ; Stone, Thomas W. / Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. In: Archives of Ophthalmology. 2009 ; Vol. 127, No. 12. pp. 1566-1571.
@article{0b9d30c388974b069728bea469943c8c,
title = "Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation",
abstract = "Objective: To compare the effect of intravitreal triamcinolone acetonide with focal/grid photocoagulation on the progression of diabetic retinopathy. Methods: We performed an exploratory analysis of participants with diabetic macular edema randomly assigned to receive laser therapy or intravitreal triamcinolone acetonide (1 or 4 mg). Fundus photographs were obtained at baseline and 1, 2, and 3 years. The main outcome measure was progression to proliferative diabetic retinopathy or worsening of 2 or more severity levels on reading-center masked assessment of 7-field fundus photographs, plus additional eyes that received panretinal photocoagulation or had a vitreous hemorrhage. Results: From July 15, 2004, through May 5, 2006, 840 eyes from 693 participants were enrolled in the study and randomly assigned to receive laser therapy (n=330), 1 mg of triamcinolone acetonide (n=256), or 4 mg of triamcinolone acetonide (n=254). The cumulative probability of progression of retinopathy at 2 years was 31{\%} (laser group), 29{\%} (1-mg group), and 21{\%} (4-mg group) (P=.64 in the 1-mg group and .005 in the 4-mg group compared with the laser group). These differences appeared to be sustained at 3 years. Conclusions: Intravitreal triamcinolone acetonide (4 mg) appeared to reduce the risk of progression of diabetic retinopathy. Given the exploratory nature of this analysis and because intravitreal triamcinolone adverse effects include cataract formation and glaucoma, use of this treatment merely to reduce the rates of progression of proliferative diabetic retinopathy or worsening of the level of diabetic retinopathy does not seem warranted at this time.",
author = "Bressler, {Neil M} and Edwards, {Allison R.} and Beck, {Roy W.} and Flaxel, {Christina J.} and Glassman, {Adam R.} and Ip, {Michael S.} and Craig Kollman and Kuppermann, {Baruch D.} and Stone, {Thomas W.}",
year = "2009",
month = "12",
doi = "10.1001/archophthalmol.2009.308",
language = "English (US)",
volume = "127",
pages = "1566--1571",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation

AU - Bressler, Neil M

AU - Edwards, Allison R.

AU - Beck, Roy W.

AU - Flaxel, Christina J.

AU - Glassman, Adam R.

AU - Ip, Michael S.

AU - Kollman, Craig

AU - Kuppermann, Baruch D.

AU - Stone, Thomas W.

PY - 2009/12

Y1 - 2009/12

N2 - Objective: To compare the effect of intravitreal triamcinolone acetonide with focal/grid photocoagulation on the progression of diabetic retinopathy. Methods: We performed an exploratory analysis of participants with diabetic macular edema randomly assigned to receive laser therapy or intravitreal triamcinolone acetonide (1 or 4 mg). Fundus photographs were obtained at baseline and 1, 2, and 3 years. The main outcome measure was progression to proliferative diabetic retinopathy or worsening of 2 or more severity levels on reading-center masked assessment of 7-field fundus photographs, plus additional eyes that received panretinal photocoagulation or had a vitreous hemorrhage. Results: From July 15, 2004, through May 5, 2006, 840 eyes from 693 participants were enrolled in the study and randomly assigned to receive laser therapy (n=330), 1 mg of triamcinolone acetonide (n=256), or 4 mg of triamcinolone acetonide (n=254). The cumulative probability of progression of retinopathy at 2 years was 31% (laser group), 29% (1-mg group), and 21% (4-mg group) (P=.64 in the 1-mg group and .005 in the 4-mg group compared with the laser group). These differences appeared to be sustained at 3 years. Conclusions: Intravitreal triamcinolone acetonide (4 mg) appeared to reduce the risk of progression of diabetic retinopathy. Given the exploratory nature of this analysis and because intravitreal triamcinolone adverse effects include cataract formation and glaucoma, use of this treatment merely to reduce the rates of progression of proliferative diabetic retinopathy or worsening of the level of diabetic retinopathy does not seem warranted at this time.

AB - Objective: To compare the effect of intravitreal triamcinolone acetonide with focal/grid photocoagulation on the progression of diabetic retinopathy. Methods: We performed an exploratory analysis of participants with diabetic macular edema randomly assigned to receive laser therapy or intravitreal triamcinolone acetonide (1 or 4 mg). Fundus photographs were obtained at baseline and 1, 2, and 3 years. The main outcome measure was progression to proliferative diabetic retinopathy or worsening of 2 or more severity levels on reading-center masked assessment of 7-field fundus photographs, plus additional eyes that received panretinal photocoagulation or had a vitreous hemorrhage. Results: From July 15, 2004, through May 5, 2006, 840 eyes from 693 participants were enrolled in the study and randomly assigned to receive laser therapy (n=330), 1 mg of triamcinolone acetonide (n=256), or 4 mg of triamcinolone acetonide (n=254). The cumulative probability of progression of retinopathy at 2 years was 31% (laser group), 29% (1-mg group), and 21% (4-mg group) (P=.64 in the 1-mg group and .005 in the 4-mg group compared with the laser group). These differences appeared to be sustained at 3 years. Conclusions: Intravitreal triamcinolone acetonide (4 mg) appeared to reduce the risk of progression of diabetic retinopathy. Given the exploratory nature of this analysis and because intravitreal triamcinolone adverse effects include cataract formation and glaucoma, use of this treatment merely to reduce the rates of progression of proliferative diabetic retinopathy or worsening of the level of diabetic retinopathy does not seem warranted at this time.

UR - http://www.scopus.com/inward/record.url?scp=73349135368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349135368&partnerID=8YFLogxK

U2 - 10.1001/archophthalmol.2009.308

DO - 10.1001/archophthalmol.2009.308

M3 - Article

C2 - 20008708

AN - SCOPUS:73349135368

VL - 127

SP - 1566

EP - 1571

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 12

ER -